Absci Documents

Absci SEC Filings

Absci Documents 2026

Absci Stock analysis

Absci Absci Corp. leverages deep learning AI and synthetic biology to create biologics for patients through its Integrated Drug Creation platform, which identifies novel drug targets and designs biotherapeutic candidates. The company's SoluPro technology enables high-throughput functional validation of AI-designed drug candidates, overcoming limitations of traditional automation labs. Partners utilize Absci's platform to predict, design, and scale production of biologic drug candidates while learning from generated data, with the firm applying generative AI to optimize target affinity, safety, and manufacturability. Absci Corp. generates revenue by providing its AI-driven drug discovery and development services to pharmaceutical partners, who pay for access to its platform and the biologic drug candidates it creates. The company's Integrated Drug Creation platform integrates AI prediction with wet lab validation, allowing partners to accelerate the discovery process for novel therapeutics. SoluPro technology serves as a key differentiator, enabling multiplex synthetic biology approaches that enhance the efficiency of drug candidate generation and validation. The firm's business model centers on delivering end-to-end solutions for biologic drug development, from target identification to scalable manufacturing, using its proprietary AI and synthetic biology capabilities. Partners benefit from Absci's ability to design optimal drug candidates based on multiple criteria, including safety and manufacturability, while Absci learns from the data generated through these collaborations to refine its platform. This closed-loop system drives continuous improvement in the company's AI models and synthetic biology processes.